Wednesday, 18 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:05 PM ET 8-K
Financial Results Nutex Health Inc. NUTX

Nutex Health Financial Results

Nutex Health reported third quarter 2026 financial results, including net income of $40.2 million and total revenue of $217.6 million. While hospital division visits increased 18.1% year-over-year, total revenue decreased 18.7% primarily due to favorable revenue recognition adjustments that occurred in the prior year period.

Term
Q3 2026
4:04 PM ET 8-K
Financial Results ARS Pharmaceuticals, Inc. SPRY

ARS Pharmaceuticals Financial Results

ARS Pharmaceuticals reported Q3 2026 financial results with total revenue of $37.7 million, driven by $33.4 million in U.S. net product revenue for neffy. The company achieved a 5% overall U.S. market share for neffy and reaffirmed its path to cash flow breakeven by year-end 2027.

Term
Q3 2026

“In August, we committed to three corporate priorities – steady market share gains with neffy, greater financial discipline with a path to cash flow breakeven by year-end 2027, and expansion of our needle-free epinephrine platform beyond anaphylaxis. I’m proud to report that our team has delivered on each.”

Donn Casale, President and Chief Executive Officer

“neffy is a highly differentiated product in a large market with genuine demand, and I am confident it can become the standard of care in the epinephrine market.”

Meg Smith, Chief Commercial Officer
4:04 PM ET 8-K
Financial Results Sumisho Air Lease Corp

Sumisho Air Lease Financial Results

Sumisho Air Lease reported Q3 2026 net income of $93.4 million on total revenues of $592.6 million, an 18.3% decrease year-over-year. The revenue decline was primarily driven by a lower weighted average net book value of flight equipment following significant aircraft sales. The company ended the quarter with 473 owned aircraft and $29.9 billion in total assets.

Term
Q3 2026
4:04 PM ET 8-K
Financial Results Affirm Holdings, Inc. AFRM

Affirm Holdings Financial Results

Affirm Holdings reported its first fiscal quarter 2027 results, achieving its 8th consecutive quarter of GAAP profitability with net income of $83 million. The company saw significant growth across key metrics, including a 35% year-over-year increase in Gross Merchandise Volume (GMV) to $14.4 billion and a 34% increase in revenue to $1.3 billion.

Term
FQ1 2027
4:04 PM ET 10-Q
Financial Results LifeStance Health Group, Inc. LFST

LifeStance Health Group Q3 2026 Results: Net Income $22.4M, Up 1978.5% YoY

LifeStance Health Group reported a significant improvement in financial performance for the third quarter of 2026, with total revenue increasing to $455.9 million compared to $363.8 million in the prior year. The company achieved a net income of $22.4 million for the quarter, a substantial increase from $1.1 million in the same period of 2025, driven by strong growth in income from operations.

Key figure
Net income $22.4M · +1978.5% YoY
4:04 PM ET 10-Q
Financial Results Steris plc STE

Steris Q2 2026 Results: Net Income $214M, Up 11.4% YoY

STERIS plc reported total revenues of $1,588.6 million for the quarter ended September 30, 2026, an 8.8% increase compared to the prior year. Net income attributable to shareholders rose to $213.7 million, driven by growth in both product and service segments, while the company continued its share repurchase program with $215.9 million spent in the first six months of the fiscal year.

Key figure
Net income $214M · +11.4% YoY
4:04 PM ET 10-Q
Financial Results Carlyle Secured Lending, Inc. CGBD

Carlyle Secured Lending Q3 2026 Results: Net Income $23.8M, Down 0.5% YoY

Carlyle Secured Lending, Inc. reported its financial results for the third quarter of 2026, highlighting stable net investment income and a consistent portfolio performance focused on senior secured loans. The company maintained its quarterly dividend and reported a steady net asset value per share despite broader market volatility.

Key figure
Net income $23.8M · -0.5% YoY
4:04 PM ET Form 4
Insider Selling Opus Genetics, Inc. IRD

Opus Genetics CEO George Magrath Sells $110K of Stock

George Magrath, CEO, sold 28,258 shares of Opus Genetics, Inc. at $3.90 a share, worth $110K in total on Nov 3, 2026. Shares held after the trade: 2,010,636 (-1.4%).

Value
$110K
Shares
28,258
Price
$3.90
Role
CEO
Holding change
-1.4%
Trade date
Nov 3, 2026
4:04 PM ET 10-Q
Financial Results Keros Therapeutics, Inc. KROS

Keros Therapeutics Q3 2026 Results: Turns Profitable, Net Income $14.2M

Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for hematological and musculoskeletal disorders. The filing highlights ongoing Phase 2 trials for rinvatercept (KER-065) and elritercept (KER-050), the latter of which is being developed in collaboration with Takeda and Hansoh.

Key figure
Net income $14.2M
4:04 PM ET 10-Q
Financial Results Aldeyra Therapeutics, Inc. ALDX

Aldeyra Therapeutics Q3 2026 Results: Net Loss of $3.76M, Loss Narrows

Aldeyra Therapeutics reported a net loss of $3.8 million for the third quarter of 2026, a significant reduction from the $7.7 million loss in the same period of 2025, primarily driven by lower research and development expenses. The company's cash position decreased to $41.0 million as of September 30, 2026, following the full repayment of its $15.0 million long-term debt during the year.

Key figure
Net loss $3.76M
4:04 PM ET 8-K
Financial Results Doximity, Inc. DOCS

Doximity Financial Results

Doximity reported fiscal 2027 second quarter revenue of $174.5 million, up 4% year-over-year, with a net income of $34.7 million. The company highlighted record engagement and heavy investment in AI, with over 190 health systems now purchasing its AI suite.

Term
Q2 2027

“We delivered another quarter of record engagement while investing heavily in AI and maintaining a 51% adjusted EBITDA margin. More than 190 health systems have now purchased our AI suite, and with UpToDate and DoseCheck, we’re extending our lead in distribution and trust.”

Jeff Tangney, co-founder and CEO of Doximity
4:04 PM ET 8-K
Investor Presentation ServisFirst Bancshares, Inc. SFBS

ServisFirst Bancshares Investor Presentation

ServisFirst Bancshares, Inc. has updated its investor presentation to include financial information and data for the current quarter. The presentation highlights the company's organic growth story and reports total assets of approximately $18.3 billion as of November 2026.

4:04 PM ET 10-Q
Financial Results Grayscale Dogecoin Trust ETF GDOG

Grayscale Dogecoin Trust ETF Q3 2026 Results: Net Income $2.07M, Up 189.2% YoY

Grayscale Dogecoin Trust ETF reported net assets of $13.6 million as of September 30, 2026, a significant increase from $3.9 million at year-end 2025, driven primarily by $12.5 million in net capital share transactions. Despite a net increase in assets, the Trust experienced a net decrease in net assets from operations of $2.78 million for the nine months ended September 30, 2026, largely due to unrealized depreciation of its DOGE holdings.

Key figure
Net income $2.07M · +189.2% YoY
4:04 PM ET 10-Q
Financial Results Maravai Lifesciences Holdings, Inc. MRVI

Maravai Lifesciences Holdings Q3 2026 Results: Net Loss of $13.8M, Loss Narrows

Maravai LifeSciences Holdings, Inc. reported its Q3 2026 financial results, noting significant revenue dependency on CleanCap® for vaccine programs and ongoing risks from organizational changes and workforce reductions. As of October 29, 2026, the company had 149,254,467 Class A and 110,684,080 Class B shares outstanding, while maintaining its status as an accelerated filer.

Key figure
Net loss $13.8M
4:04 PM ET 10-Q
Financial Results Parker-Hannifin Corp PH

Parker-Hannifin Q1 2026 Results: Net Income $884M, Up 9.4% YoY

For the quarter ended September 30, 2026, Parker-Hannifin reported net sales of $5.99 billion, an 18% increase from the prior year, and net income of $884 million. The company's balance sheet showed significant growth in total assets to $41.9 billion, primarily driven by a $9.1 billion acquisition that substantially increased goodwill and intangible assets.

Key figure
Net income $884M · +9.4% YoY
4:04 PM ET 8-K
Financial Results Mannkind Corp MNKD

Mannkind Financial Results

MannKind Corporation reported third quarter 2026 total revenues of $101.9 million, a 24% increase year-over-year, driven by the commercial launch of Furoscix ReadyFlow and strong pediatric uptake for Afrezza. The company also highlighted positive Phase 1b results for its nintedanib DPI program and a new licensing collaboration with Rose Pharma for an inhaled GLP-1.

“The third quarter marked an important transition for MannKind as we shifted from delivering on three major catalysts to executing against them. We are focused on scaling two commercial launches while supporting three programs in IPF. Furoscix ReadyFlow is off to an exceptionally strong start, and we believe Furoscix will generate more revenue in the fourth quarter than it did in the first half of 2026. ReadyFlow significantly expands the opportunity ahead and reinforces our conviction that Furoscix can be transformational for MannKind and the patients we serve.”

Michael Castagna, Chief Executive Officer of MannKind
4:04 PM ET 8-K
Financial Results Quantinuum Inc. QNT

Quantinuum Financial Results

Quantinuum reported third quarter 2026 revenue of $9.1 million, a 233% year-over-year increase, driven by expanded enterprise reach and the largest cloud agreement in company history. The company raised its full-year 2026 revenue guidance to a range of $32 million to $35 million while maintaining a strong cash position of $1.94 billion.

Term
Q3 2026

“In the third-quarter, we extended our technology leadership in the critical area of fault-tolerance, added to our customer base, and expanded our routes to market. This accelerated momentum is supporting our raised revenue outlook for 2026 and giving us more confidence than ever in the opportunity in front of us.”

Rajeeb Hazra, President and Chief Executive Officer of Quantinuum
4:04 PM ET 8-K
Financial Results Sintx Technologies, Inc. SINT

Sintx Technologies Financial Results

SINTX Technologies reported record third quarter 2026 revenue of $2.2 million, a more than tenfold increase compared to the prior year. The company significantly reduced its net loss by 55% to $1.6 million while advancing the commercialization of its SiNAPTIC Foot & Ankle Osteotomy Wedge System.

Term
Q3 2026

“Our third-quarter results represent a meaningful milestone in the commercial transformation of SINTX Technologies. The substantial increase in quarterly revenue, combined with significant improvements in gross profit and operating performance, demonstrates the potential of our advanced manufacturing platform as we convert investments over the past several years into revenue-building commercial opportunities.”

Eric Olson, Chief Executive Officer of SINTX

“We believe our performance this quarter demonstrates measurable progress toward building a commercially focused advanced materials company. With improving operating performance, expanding commercial activities, and continued investment in our proprietary technologies, we believe SINTX is well positioned to pursue additional growth opportunities in 2027.”

Eric Olson, Chief Executive Officer of SINTX
4:03 PM ET 8-K
Clinical Trial Data Eton Pharmaceuticals, Inc. ETON

Eton Pharmaceuticals Clinical Trial Data

Eton Pharmaceuticals announced preliminary results from a pilot study of ET-700 for Wilson disease, demonstrating significantly improved gastrointestinal tolerability compared to GALZIN. While ET-700 showed a lower rate of adverse events (8% vs 67% for GALZIN), its copper absorption inhibition was more modest (12% reduction vs 46% for GALZIN), leading the company to plan additional study arms in 2027 for faster-release formulations.

“The tolerability findings are exciting and reinforce our belief that a slower release zinc can improve tolerability, which is a notorious issue with zinc treatment. We are encouraged by the initial results, which showed a benefit over placebo, and our next objective is to improve ET-700’s effect on copper absorption.”

Sean Brynjelsen, Chief Executive Officer of Eton Pharmaceuticals
4:03 PM ET 10-Q
Financial Results Grayscale Chainlink Trust ETF GLNK

Grayscale Chainlink Trust ETF Q3 2026 Results: Net Income $76.4M, Up 724.9% YoY

Grayscale Chainlink Trust ETF reported a significant increase in net assets to $173.1 million as of September 30, 2026, driven by $35.2 million in net increase from operations and $64.0 million in net capital share transactions. The Trust successfully uplisted to NYSE Arca on December 2, 2025, and saw its outstanding shares grow from 6.8 million to 13.7 million during the first nine months of 2026.

Key figure
Net income $76.4M · +724.9% YoY
4:03 PM ET 10-Q
Financial Results Gulfport Energy Corp GPOR ▶ Call

Gulfport Energy Q3 2026 Results: Net Income $96.4M, Down 13.5% YoY

Gulfport Energy Corporation reported 17,412,032 shares of common stock outstanding as of October 29, 2026. The filing highlights the company's continued operations in the Utica and SCOOP plays, supported by a senior secured reserve-based revolving credit facility and senior notes due in 2026 and 2029.

Key figure
Net income $96.4M · -13.5% YoY
4:03 PM ET 10-Q
Financial Results Shift4 Payments, Inc. FOUR

Shift4 Payments Q3 2026 Results: Net Income $38M, Up 35.7% YoY

Shift4 Payments reported gross revenue of $1.32 billion for Q3 2026, a 12% increase year-over-year, though net income attributable to common stockholders decreased to $28 million for the first nine months of 2026 compared to $54 million in 2025. The company's balance sheet shows a significant increase in cash to $1.24 billion and total assets reaching $9.47 billion as of September 30, 2026.

Key figure
Net income $38M · +35.7% YoY
4:03 PM ET Form 4
Insider Selling Kforce Inc KFRC

Kforce Insider David L. Dunkel Sells $175K of Stock

David L. Dunkel sold 3,000 shares of Kforce Inc at $58.10 to $59.10 a share (average $58.31) in 4 transactions, worth $175K in total between Nov 3, 2026 and Nov 4, 2026. Shares held after the trade: 503,329 (-0.1%).

Value
$175K
Shares
3,000
Average price
$58.31
Holding change
-0.1%
Trade date
Nov 3, 2026 to Nov 4, 2026
4:03 PM ET 8-K
Financial Results Blink Charging Co. BLNK

Blink Charging Financial Results

Blink Charging reported Q3 2026 financial results, achieving its first-ever positive quarterly Adjusted EBITDA of $0.2 million, one quarter ahead of target. Total revenue was $18.4 million, a 32% decrease year-over-year, primarily due to portfolio rationalization and the divestiture of its car-sharing business.

Term
Q3 2026

“Achieving positive adjusted EBITDA a quarter ahead of our target is a monumental milestone and it reflects the discipline we have built across Blink over the past eighteen months.”

Mike Battaglia, Chairman and CEO

“Delivering positive adjusted EBITDA of $0.2 million in the third quarter, compared with a $(7.3) million loss a year ago, is a testament to our focus on operational efficiency and cost management.”

Michael Bercovich, Chief Financial Officer
4:03 PM ET 10-Q
Financial Results Bruker Corp BRKR

Bruker Q3 2026 Results: Net Loss of $112M, Loss Widens

Bruker Corporation reported a consolidated net loss of $109.7 million for the third quarter of 2026, compared to a loss of $58.5 million in the prior year period, primarily driven by a $174.5 million goodwill impairment charge. Despite the net loss, total revenue grew slightly to $874.0 million from $860.5 million year-over-year, supported by growth in service and other revenue.

Key figure
Net loss $112M
4:03 PM ET 10-Q
Financial Results Nutex Health Inc. NUTX

Nutex Health Q3 2026 Results: Net Income $40.2M, Down 27.4% YoY

Nutex Health Inc. reported a net income attributable to the company of $152.9 million for the nine months ended September 30, 2026, a significant increase from $59.0 million in the prior year period. Despite a decrease in total revenue from $723.6 million to $644.9 million, the company achieved higher operating income due to a substantial reduction in stock-based compensation expenses.

Key figure
Net income $40.2M · -27.4% YoY
4:03 PM ET 8-K
Financial Results Biodesix Inc BDSX

Biodesix Financial Results

Biodesix reported Q3 2026 total revenue of $24.0 million, a 10% year-over-year increase driven by a 16% rise in Diagnostic Testing revenue. Despite the growth, the company revised its full-year 2026 revenue guidance downward to $101-$103 million, citing slower-than-expected sales representative contributions and seasonality.

Term
Q3 2026

“Biodesix delivered another quarter of year-over-year growth, with total revenue increasing 10%, Diagnostic Testing revenue increasing 16%, test volumes increasing 24%, and gross margin remaining strong at 81%. However, our growth was below our expectations, and we understand the principal drivers: fewer contributing sales representatives than planned limited new physician and account growth; greater-than-anticipated seasonality, primarily in primary care, reduced ordering frequency among otherwise stable base customers; and delays in external customer dependencies postponed the start of Development Services projects and the associated revenue recognition.”

Scott Hutton, Chief Executive Officer

“The factors that impacted the quarter were largely execution and timing related rather than a change in demand, clinical utility, or market opportunity. We have identified the drivers, taken corrective actions, and entered the fourth quarter with a larger sales organization positioned for improved execution.”

Scott Hutton, Chief Executive Officer
4:03 PM ET 10-Q
Financial Results Grayscale Bittensor Trust (TAO) GTAO

Grayscale Bittensor Trust Q3 2026 Results: Turns Profitable, Net Income $4.87M

Grayscale Bittensor Trust (TAO) reported a significant increase in net assets to $17.7 million as of September 30, 2026, driven by $6.5 million in capital share issuances and $3.2 million in net increase from operations. The Trust's Principal Market NAV per Share rose to $5.66 from $4.24 at the end of 2025, despite ongoing net investment losses due to the Sponsor's Fee.

Key figure
Net income $4.87M
4:03 PM ET 8-K
Financial Results Iren Ltd IREN

Iren Financial Results

IREN reported Q1 FY27 financial results with total revenue increasing 66% sequentially to $228 million, driven by AI Cloud revenue nearly tripling to $200 million. The company reported a net loss of $263 million but achieved positive Adjusted EBITDA of $66 million, while noting its $4 billion ARR target is now expected by January or February 2027.

“This quarter Horizon 1 went into service for Microsoft with NVIDIA Exemplar status, AI Cloud revenue nearly tripled to $200 million, and operating ARR doubled to a billion. The more than $4 billion of contracted ARR is funded and now targeted for January, after a customer-requested design change and supplier timing moved it from year-end; it may extend to the end of February.”

Daniel Roberts, Co-Founder and Co-CEO of IREN
4:03 PM ET 10-Q
Financial Results Perdoceo Education Corp PRDO

Perdoceo Education Q3 2026 Results: Net Income $44.4M, Up 11.4% YoY

Perdoceo Education Corp reported a net income of $44.4 million for the third quarter of 2026, up from $39.9 million in the prior year period, driven by a 1.9% increase in total revenue. For the first nine months of 2026, net income reached $146.3 million compared to $124.6 million in 2025, reflecting improved operating margins and higher interest income. The company maintained a strong liquidity position with $776.9 million in cash and short-term investments as of September 30, 2026.

Key figure
Net income $44.4M · +11.4% YoY

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.